Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort

Background Tocilizumab and baricitinib are recommended treatment options for hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and safety in a head-to-head comparison is scarce. Methods Hospitalized COVID-19 patients requiring oxygen were treated with tocilizumab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Infection 2023-08, Vol.51 (4), p.851-858
Hauptverfasser:	Karolyi, Mario, Gruebl, Andreas, Omid, Sara, Saak, Magdalena, Pawelka, Erich, Hoepler, Wolfgang, Kelani, Hasan, Kuran, Avelino, Laferl, Hermann, Ott, Clemens, Pereyra, David, Santol, Jonas, Seitz, Tamara, Traugott, Marianna, Assinger, Alice, Wenisch, Christoph, Zoufaly, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trials COVID-19 COVID-19 Drug Treatment Dexamethasone Drug-Related Side Effects and Adverse Reactions Family Medicine Female General Practice Hospitalization Hospitals Humans Infectious Diseases Internal Medicine Male Mechanical ventilation Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Mortality Oxygen Patients Side effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!